Posted by Michael Wonder on 01 Nov 2023
X4 Pharmaceuticals announces FDA acceptance with priority review of US NDA for mavorixafor in WHIM syndrome
31 October 2023 - FDA sets a PDUFA target action date of 30 April 2024.
X4 Pharmaceuticals today announced that the US FDA has accepted for filing the company’s new drug application for once daily, oral mavorixafor to treat individuals aged 12 and older with WHIM (warts, hypogammaglobulinaemia, infections and myelokathexis) syndrome, a rare, primary immunodeficiency.
